rss
Ann Rheum Dis 1990;49:926-928 doi:10.1136/ard.49.11.926
  • Research Article

5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.

  1. J A Casas,
  2. P A Saway,
  3. I Villarreal,
  4. C Nolte,
  5. B L Menajovsky,
  6. E E Escudero,
  7. W D Blackburn,
  8. G S Alarcón,
  9. C P Subauste
  1. Department of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.

      Abstract

      A six month controlled study of 5-fluorouracil in the treatment of scleroderma showed a modest benefit in skin scores, Raynaud's phenomenon, and patients' global assessment. Visceral organ and hand function were unaffected. Mild to moderate toxicity was common in the 5-fluorouracil treated patients but usually responded to dose reduction. Two patients receiving 5-fluorouracil died from causes seemingly unrelated to treatment. Significant clinical improvement in scleroderma was not noted in the first six months of treatment with 5-fluorouracil.

      This Article

      1. Abstract
      2. PDF

      Responses

      1. Submit a response
      2. No responses published

      Register for free content

      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.